Variables | β | SE (β) | OR (95% CI) |
Demographic data and vascular risk factors:1-150 | |||
Hypertension | 1.1942 | 0.1637 | 3.30 (2.39–4.55) |
Obesity | 0.8052 | 0.3295 | 2.24 (1.17–4.27) |
Diabetes | 0.4725 | 0.1798 | 1.60 (1.13–2.28) |
Female sex | −0.3739 | 0.1581 | 0.69 (0.50–0.94) |
Atrial fibrillation | −0.9531 | 0.2154 | 0.38 (0.25–0.59) |
Demographic data, vascular risk factors and clinical features:1-151 | |||
Hypertension | 1.2944 | 0.1690 | 3.65 (2.62–5.08) |
Non-sudden stroke onset (h) | 0.6118 | 0.1571 | 1.84 (1.14–2.36) |
Diabetes | 0.4988 | 0.1854 | 1.65 (1.14–2.37) |
Hyperlipidaemia | 0.4134 | 0.2001 | 1.51 (1.02–2.23) |
Speech disturbances | −0.6628 | 0.1617 | 0.51 (0.37–0.71) |
Atrial fibrillation | −0.7863 | 0.2223 | 0.45 (0.29–0.70) |
Headache | −0.9941 | 0.2651 | 0.37 (0.22–0.62) |
Dizziness | −2.0106 | 0.7395 | 0.13 (0.03–0.57) |
Demographic data, vascular risk factors, clinical features, and neuroimaging data:1-152 | |||
Internal capsule involvement | 2.7513 | 0.2360 | 15.66 (9.86–24.87) |
Hypertension | 1.4479 | 0.1875 | 4.25 (2.95–6.14) |
Diabetes | 0.6685 | 0.2047 | 1.95 (1.31–2.91) |
Non-sudden stroke onset (h) | 0.4397 | 0.1717 | 1.55 (1.11–2.17) |
Speech disturbances | −0.7440 | 0.1796 | 0.47 (0.33–0.67) |
Middle cerebral artery topography | −0.7915 | 0.2017 | 0.45 (0.30–0.67) |
Headache | −1.1757 | 0.2788 | 0.31 (0.18–0.53) |
Congestive heart failure | −1.5356 | 0.5766 | 0.21 (0.07–0.67) |
Basal ganglia involvement | −1.9265 | 0.3140 | 0.14 (0.08–0.27) |
Thalamic involvement | −2.4895 | 0.5340 | 0.08 (0.03–0.24) |
Demographic data, vascular risk factors, clinical features, neuroimaging data, and outcome:1-153 | |||
Internal capsule involvement | 2.6514 | 0.2398 | 14.17 (8.86–22.68) |
Hypertension | 1.4829 | 0.1913 | 4.40 (3.02–6.41) |
Diabetes | 0.7750 | 0.2108 | 2.17 (1.44–3.28) |
Pons topography | 0.4370 | 0.3207 | 1.55 (0.82–2.90) |
Middle cerebral artery involvement | −0.6475 | 0.2095 | 0.52 (0.35–0.79) |
Speech disturbances | −0.7308 | 0.1834 | 0.48 (0.34–0.69) |
Headache | −1.1022 | 0.2852 | 0.33 (0.19–0.58) |
Urinary complications | −1.1058 | 0.3800 | 0.33 (0.16–0.70) |
Rheumatic heart disease | −1.2722 | 0.7482 | 0.28 (0.06–1.21) |
Congestive heart failure | −1.4847 | 0.5868 | 0.23 (0.07–0.72) |
Cardiac events | −1.7466 | 0.7743 | 0.17 (0.04–0.80) |
Neurological complications | −1.8952 | 0.5273 | 0.15 (0.05–0.42) |
Thalamic involvement | −2.3771 | 0.5463 | 0.09 (0.03–0.27) |
↵1-150 β=−2.6900, SE (β)=0.4971, goodness of fit χ2=8.4581, df=8, p=0.3900.
↵1-151 β=−2.4153, SE (β)=0.5368, goodness of fit χ2=12.2125, df=8, p=0.1420.
↵1-152 β=−2.1216, SE (β)=0.5944, goodness of fit χ2=8.1408, df=8, p=0.4198.
↵1-153 β=−2.2323, SE (β)=0.6102, goodness of fit χ2=9.6255, df=8, p=0.2923.